Tracers / [211At]At-L3-Lu

[211At]At-L3-Lu

Also written as [At-211]L3-Lu

Radionuclide: At-211 t½ 431 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Prostate cancer

What it is

Compound class: PSMA-targeted low-molecular-weight agent (tin precursor for radiohalogenation)
Target / mechanism: PSMA (prostate-specific membrane antigen) PMID 38703587
Clinical application: Targeted alpha-particle therapy for PSMA-positive prostate cancer (preclinical) PMID 38703587
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	custom manifold	HPLC+SPE	87 ± 5% yes	>95%	L3-Lu tin precursor	38703587 2024 Nucl Med Biol A solution of 211At in methanol containing NCS (37–740 MBq, 200–500 μL, 0.2 mg/mL NCS) was added to a half-dram glass vial containing 100 μg (equivalent to 77 nmole for the YF2 precursor, and 81 nmole for the L3-Lu precursor) of the YF2 tin precursor — The RCY using this approach for [211At]L3-Lu was essentially identical (87 ± 5%; n=7, decay-corrected)

Need this precursor?We can point you to suppliers for [211At]At-L3-Lu, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 38703587. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 38703587: 'L3-Lu tin precursor (10)'.